-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19

Benzinga·11/06/2026 16:16:08
Listen to the news
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $18 to $19.